S&P 500
7,619.98
−0.48% Mon
Executive dashboard
Nasdaq Comp.
26,186.41
−0.56% Mon
Dow
52,421.20
−0.29% Mon
Russell 2000
2,892.24
−0.40% Mon
VIX
17.10
+7.95% Mon
U.S. 2Y
4.65%
+2 bp d/d
U.S. 10Y
4.97%
+1 bp d/d; >5% overnight
Dollar index
99.65
+0.19% daily bar
WTI
$103.12
+1.57% daily bar
Gold
$4,330.30
−0.51% daily bar
S&P future
7,674
feed basis differs
Nasdaq future
29,386
no comparable % asserted
| Region / index | Level | Move | Status at cutoff |
|---|---|---|---|
| Nikkei 225 | 63,629.06 | +0.21% | Tuesday close. Yahoo |
| Hang Seng | 24,727.11 | −0.76% | Live 14:15 HKT; not final. Yahoo |
| Shanghai Composite | 3,870.19 | −0.39% | Live 14:15 CST; not final. Yahoo |
| Euro Stoxx 50 | 6,260.38 | −1.02% Mon | Tuesday cash pre-open; futures about +0.06% in Reuters snapshot. Reuters |
| DAX | 25,440.81 | −0.50% Mon | Tuesday cash pre-open; futures about −0.02%. Yahoo |
| FTSE 100 | 10,697.60 | +0.44% Mon | Tuesday cash pre-open; futures about −0.21%. Yahoo |
10Y pierced 5%; Fed starts today
Reuters recorded the U.S. 10-year above 5.021% overnight, the highest since 2007. CME FedWatch showed a 92.3% implied chance of a 25 bp hike tomorrow versus 59.4% one week earlier. The surprise risk is now the path and projections, not merely hike/no hike. CME
Oil is the cross-asset stressor
WTI traded around $103 as Saudi pipeline damage and stalled Gulf–Iran talks threatened supply; Reuters says a prolonged pipeline shutdown could affect as much as 4% of global supply. Higher crude presses inflation, margins and duration multiples. Reuters
AI hardware sold off hard
Monday's SOX fell about 5.2%; COHR −12.73%, VRT −7.65%, ANET −5.90%, INTC −5.59%, AVGO −4.77% and AMD −4.40%. The catalyst is AI-safety/capex-duration concern amplified by rates—not a newly filed demand collapse. Reuters
Market drivers
Macro, central banks and rotation
- Fed: the Sep. 15–16 meeting includes a Summary of Economic Projections. FedWatch at 01:17 CT priced 92.3% for 375–400 bp from 350–375 bp. Probabilities are market-implied, not forecasts. Fed calendar
- BOJ: Reuters reports consensus for a 25 bp rise to 1.25% Friday; Japan's 10Y touched 3.025%, adding global term-premium pressure. Reuters
- Today's U.S. tape arrives later: Empire manufacturing is due 08:30 ET and weekly ADP 08:15 ET—14:30/14:15 CEST, after this publication. CME calendar
- Rotation: Monday's broad indices fell modestly but semiconductor hardware dropped much more; software ETF IGV gained about 5% while SOXX fell about 5%, per CNBC. CNBC
Geopolitics, regulation and verified unusual moves
- Middle East: renewed Houthi attacks, the Saudi east–west pipeline outage and postponed Hormuz talks keep a nonlinear oil tail risk. The exact duration and lost barrels remain unknown. Reuters
- AI policy: industry leaders called for slower frontier-model development; U.S. senators are discussing precaution requirements. President Trump publicly rejected the slowdown narrative. Policy direction is contested. Reuters
- VRT: −7.65% on 2.28× trailing-20-session volume; COHR: −12.73% on 1.61×. These are verified unusual moves, but one-day volume does not prove lasting fundamental deterioration. VRT history · COHR history
- Primary filings check: reviewed SEC submissions for NVDA, ANET, VRT, COHR, IONQ, QUBT, VKTX, ALT and LLY. No new operating filing dated Sep. 14 appeared; recent entries were mainly ownership/Rule 144. NVDA example
Theme dashboards
Hardware breadth broke; evidence is narrative-led
- Laggards: COHR −12.73%, VRT −7.65%, ANET −5.90%, INTC −5.59%, MU −5.25%, AVGO −4.77%, AMD −4.40%, NVDA −3.36%. SMH fell 4.75% on 1.58× 20-day volume.
- Relative leader: Oracle still fell 3.65%; Monday offered no clean hardware leader in the tracked set.
- Counterevidence: Nvidia released CUDA-Q Logical and an independent QUOPS benchmark implementation; Fermilab says the workflow cut one architecture task from five months to three weeks. It supports ecosystem tooling, not near-term revenue. Nvidia IR
- Risk: 10Y >5%, debt-funded capex, customer concentration, exports, power constraints and safety regulation can compress multiples before demand changes.
Stocks resisted Monday; trend remains damaged
- Monday: IONQ +2.04%, QBTS +0.18%, RGTI flat, QUBT −0.25%—relative strength versus chips.
- 20 sessions: QBTS −20.50%, IONQ −18.94%, RGTI −18.86%, QUBT −11.54%. A one-day divergence is not a trend reversal.
- Primary catalyst: Nvidia's open fault-tolerant orchestration layer and Sandia's QUOPS benchmark may improve comparability; it does not validate any listed vendor's commercial advantage. Release
- Accounting risk: QUBT's Sep. 8 8-K/A adds acquired NHanced financials and pro formas; acquisition effects complicate organic comparisons. SEC
Large-cap rebound; VKTX event clock persists
- Monday: LLY +2.02%, NVO +0.88%, ALT +0.92%, while VKTX −1.41%; XBI gained 0.90%. Peptide exposure outperformed semiconductors.
- ALT evidence: 100-patient Phase 2 RECLAIM met its heavy-drinking-days endpoint: −1.45 LS-mean treatment effect, p=0.0014. Nausea was 44% vs 24%, vomiting 18% vs 6%, and drug-related discontinuations 10% vs 0%; an FDA end-of-Phase-2 meeting is planned. Registry had no posted results at cutoff. Altimmune · Registry
- VKTX: Q3 Phase 1 maintenance data remain undated: ~180 adults, weekly/every-other-week/monthly injectable and oral regimens; safety/tolerability/PK are objectives and weight durability is exploratory. Viking
- Risks: small samples, GI tolerability, duration, manufacturing, reimbursement, competition, dilution and binary gaps.
Ranked conditional ideas
Bullish list: no compelling actionable opportunity before U.S. price discovery and the FOMC. Monday confirmed broad AI-hardware damage while overnight futures signals differ by feed/session basis. Waiting is an active decision; all entries below require confirmation.
Bearish / short / avoid
ORCL · Oracle
Exchange/risk: NYSE; mega-cap cloud; high event, capex and debt sensitivity. Classification: avoid / confirmation-only bearish. Applicable horizon: day trade and 1–4 weeks; not a structural 3–12+ month short. Direction: uncertain; short losses can be unlimited.
Thesis/catalyst/evidence: Monday closed $144.79, −3.65%, on 1.57× 20-day volume; the prior report's $149.84 breakdown trigger was crossed. Five-day low is $141.01. AI-capex and rate anxiety remain catalysts. Counterargument: OCI/backlog conversion or a post-Fed duration rally can squeeze the stock; oversold conditions can reverse abruptly.
Entry/confirmation: only a break and failed reclaim of $141.00; alternatively remain out. Invalidation/downside: bearish case weakens above $149.10 20-day average and is invalid above $152 on a closing basis; no target asserted. Key risks: squeeze, backlog conversion, debt/credit, capex, power, concentration and Fed. Borrow availability/fees unknown. 10-Q
VRT · Vertiv
Exchange/risk: NYSE; large-cap, high-beta AI power/cooling. Classification: tactical avoid / bearish only after confirmation. Applicable horizon: day and 1–4 weeks; structural 3–12+ month thesis remains unbroken. Direction: uncertain.
Thesis/catalyst/evidence: $237.39 close, −7.65%, 2.28× volume; 20-session return −19.21% and 20-day average $263.52. Rates and AI-capex narrative pressure duration. Counterargument: data-center power scarcity supports long-run orders; Monday may be capitulation.
Entry/confirmation: failed $245–$250 rebound followed by break below $226.94. Invalidation/downside: close above $263.52; stronger invalidation above $270. Key risks: violent oversold bounce, order wins, execution, supply/input costs, valuation and Fed. Short risk unlimited; borrow terms unknown. History · SEC submissions
COHR · Coherent
Exchange/risk: NYSE; mid/large-cap optical supplier; high-beta cyclicality. Classification: avoid, not chase-short. Applicable horizon: day and 1–4 weeks. Direction: uncertain.
Thesis/catalyst/evidence: $266.50, −12.73%, 1.61× volume and −18.21% over 20 sessions. The close sits just above $265.49 five-day low and below $289.62 20-day average. Counterargument: AI optical demand and an oversold rebound can overwhelm a late short.
Entry/confirmation: no chase; only after a failed $280–$290 reclaim and renewed break below $265. Invalidation/downside: close above $290; stronger above $300. Key risks: squeeze, hyperscaler demand, product ramps, supply, leverage, customer concentration and rates. Borrow terms unknown. History · SEC
Watchlist · confirmation required
NVDA · Nvidia
Exchange/risk: Nasdaq; mega-cap semiconductor, high concentration/export risk. Classification: bullish repair watch. Applicable horizon: 1–4 weeks and 3–12+ months; not a current day-trade long. Direction: uncertain.
Thesis/evidence: CUDA-Q Logical broadens hybrid quantum tooling, but Monday −3.36% to $210.96 and −6.31% over 20 sessions. Counter: 10Y >5%, AI-policy risk and $207.25 20-day low nearby. Entry/confirmation: hold $207 then close above $219.45 20-day average with SMH breadth. Invalidation/downside: close below $207; then no bottom assumed. Risks: capex, China/export controls, customers, competition, supply and valuation. Nvidia IR
ANET · Arista Networks
Exchange/risk: NYSE; large-cap, high-beta networking. Classification: repair watch. Applicable horizon: day/1–4 weeks; long term requires valuation review. Direction: uncertain.
Thesis/evidence: structural scale-out networking demand; Monday −5.90% to $187.81 on 1.13× volume, wiping out Friday's breakout. Counter: $181.27 20-day low offers nearby support. Entry/confirmation: regain $192.61 20-day average, then $200.68 five-day high with sector breadth. Invalidation/downside: close below $181. Risks: hyperscaler concentration, capex pauses, competition, exports, supply and valuation. History
IONQ · IonQ
Exchange/risk: NYSE; small-cap/high-volatility, pre-profit; extreme acquisition, technical and dilution risk. Classification: relative-strength watch only. Applicable horizon: day and 1–4 weeks. Direction: uncertain.
Thesis/evidence: +2.04% Monday against a chip selloff; quantum tooling news is ecosystem-positive. Yet $37.50 is −18.94% over 20 sessions and below $40.42 average. Guidance includes acquired SkyWater. Counter: bounce may be short-lived; integration obscures organic economics. Entry/confirmation: close above $40.42, stronger above $44.43. Invalidation/downside: below $35.00. Risks: roadmap validation, contracts, burn, M&A, dilution, warrants, gaps and squeeze. Borrow terms unknown. IonQ
ALT · Altimmune
Exchange/risk: Nasdaq; small-cap clinical biotech, pre-commercial, binary and dilution risk. Classification: clinical/regulatory watch. Applicable horizon: 1–4 weeks and 3–12+ months only after FDA-path clarity. Direction: uncertain.
Thesis/evidence: RECLAIM's primary and key secondary endpoints were statistically significant; objective PEth supported self-report. $3.30 is +12.24% over 20 sessions. Counter: N=100, no posted registry results, GI AEs and 10% drug-related discontinuations; Phase 3 design and financing remain open.
Entry/confirmation: FDA end-of-Phase-2 clarity plus close above $3.55; not before. Invalidation/downside: regulatory delay, unfavorable Phase 3 burden, financing or close below $2.90. Cash/runway: latest 10-Q must be reviewed before sizing; no runway estimate asserted here. Competition: approved/off-label AUD options and other incretins. 10-Q · Trial
VKTX · Viking Therapeutics
Exchange/risk: Nasdaq; small-cap clinical biotech, pre-revenue; binary and dilution risk. Classification: event watch, not pre-data long. Applicable horizon: 1–4 weeks around data; 3–12+ months only after full evidence. Direction: uncertain.
Thesis/catalyst: Q3 Phase 1 maintenance readout across injection/oral schedules; Phase 3 VANQUISH programs advance the registrational path. Counter: maintenance study is exploratory and small; $31.53 is below $33.49 20-day average and at $31.39 five-day low.
Entry/confirmation: acceptable safety/durability plus close above $34.81; no pre-data sizing. Invalidation/downside: weak durability, safety/discontinuation issue, delay or close below $31.39. Cash: June cash/investments about $502M per issuer; runway depends on accelerating Phase 3 spend. Risks: GI/safety, endpoints/statistics, FDA path, LLY/NVO competition, manufacturing and dilution. Viking
Scores are 0–100. Higher Risk means riskier. Thesis Confidence grades evidence quality—not probability or certainty of profit. Entries are confirmation rules, not guaranteed fills.
Changes versus the 2026-09-14 report
- Regime remains risk-off/event-heavy, but the source changed: yesterday's futures warning became a cash selloff; today 10Y >5%, WTI around $103 and the FOMC dominate.
- ORCL bearish trigger confirmed: $144.79 closed below the prior $149.84 trigger. The new entry rule moves lower to $141 to avoid chasing.
- AI watchlist damaged: ANET failed its $200 breakout and VRT moved from watch to tactical avoid after −7.65% on 2.28× volume. COHR is newly added as avoid after −12.73%.
- Quantum relative strength appeared: IONQ rose while chips fell, but the 20-day trend remains sharply negative; it stays watch-only.
- Peptide biotech improved relatively: LLY/NVO/ALT rose and XBI gained while hardware sold off. ALT is added on verified Phase 2 statistics but awaits FDA-path clarity; VKTX remains an undated Q3 binary watch.
- New primary evidence: Nvidia's Sep. 14 CUDA-Q Logical/QUOPS release provides a real quantum-platform catalyst, but no near-term revenue figure.
- Correction discipline: an initial SEC CIK lookup mapped to OKLO rather than ALT; it was rejected and the correct ALT CIK 1326190 was verified before publication. No Oklo claim is used.
Important catalysts · immediate and next 7–30 days
Sep. 15–16 — FOMC; decision/SEP Sep. 16
CME priced 92.3% for a 25 bp hike at cutoff; guidance and dots are the larger duration-equity risk. Federal Reserve · CME
CME priced 92.3% for a 25 bp hike at cutoff; guidance and dots are the larger duration-equity risk. Federal Reserve · CME
Sep. 16 · 14:30 CEST — U.S. import/export prices
Fresh external-inflation evidence before the Fed decision; not available at 08:30 Italy. BLS
Fresh external-inflation evidence before the Fed decision; not available at 08:30 Italy. BLS
Sep. 18 — BOJ decision
Reuters reports expectations for +25 bp to 1.25%; yen/JGB spillovers matter for global duration. Reuters
Reuters reports expectations for +25 bp to 1.25%; yen/JGB spillovers matter for global duration. Reuters
Sep. 24 — U.S. international transactions
Capital-flow and external-balance update. BEA
Capital-flow and external-balance update. BEA
Sep. 28–Oct. 2 — EASD 2026
Potential obesity/diabetes evidence flow, including Novo's Sep. 29 symposium. Unpublished outcomes are not assumed. Novo/EASD
Potential obesity/diabetes evidence flow, including Novo's Sep. 29 symposium. Unpublished outcomes are not assumed. Novo/EASD
Sep. 29 — August JOLTS
Labor-demand input for the next Fed path. BLS
Labor-demand input for the next Fed path. BLS
Sep. 30 — GDP third estimate, profits and August income/outlays
Growth, margins and inflation evidence with direct rate implications. BEA
Growth, margins and inflation evidence with direct rate implications. BEA
By Sep. 30, undated — VKTX Phase 1 maintenance data
Issuer-guided Q3 window; non-registrational safety/tolerability/PK study with exploratory weight durability. Viking
Issuer-guided Q3 window; non-registrational safety/tolerability/PK study with exploratory weight durability. Viking
Sep. 29/30 — IONQ warrant trading cessation / expiry
Capital-structure flows may distort prices; no claim about borrow is made. SEC
Capital-structure flows may distort prices; no claim about borrow is made. SEC
By mid-October — ALT FDA-path watch
Company plans an end-of-Phase-2 meeting request for RECLAIM, but no meeting date is published; this is a watch window, not a dated catalyst. Altimmune
Company plans an end-of-Phase-2 meeting request for RECLAIM, but no meeting date is published; this is a watch window, not a dated catalyst. Altimmune
Bottom line by horizon
Day trade
Stance: defensive. Do not chase Monday's hardware gap lower or treat conflicting overnight-futures bases as certainty. Favor only failed reclaims/breaks with U.S. breadth and volume confirmation.
Biggest risk: oil/diplomacy or Fed-expectation reversal. Invalidation: 10Y back below 4.90%, WTI below $100 and SMH reclaiming Monday's breakdown would neutralize the risk-off setup.
1–4 week swing
Stance: smaller exposure through the Fed/BOJ. Prefer cash-generative leaders after repair; avoid pre-profit duration and binary biotech without explicit sizing.
Biggest risk: oil-driven inflation plus synchronized central-bank tightening. Invalidation: a broad index higher high with falling yields/oil and improving equal-weight breadth.
3–12+ month investment
Stance: AI demand evidence survives one selloff, but demand must convert to margins and FCF. Quantum needs independent utility/economics; peptides need complete efficacy, safety, regulatory and runway analysis.
Biggest risk: cost of capital, circular financing, concentration, dilution and technical/clinical failure. Invalidation: sustained order/cash deterioration or failed clinical/technical milestones—not daily volatility.
Data quality, sources and limitations
- Live research: more than five meaningful retrieval calls covered Yahoo chart APIs, Reuters/CNBC current reporting, official Treasury/Fed/BLS/BEA/CME calendars and pricing, Nasdaq Trader, SEC submissions/filings, company IR, and ClinicalTrials.gov.
- Timestamps: U.S. cash/theme prices are Sep. 14 closes. Yahoo futures/commodities/FX and Asian data were retrieved around 08:17–08:22 CEST; Hong Kong/Shanghai were open. Official Treasury curve is Sep. 14. Europe cash values are Sep. 14 closes because Tuesday cash markets were not yet open.
- Cross-checks: U.S. closes and AI moves were checked against CNBC/Reuters; 10Y/oil against Treasury, Reuters and Yahoo; Fed odds against CME; company claims against SEC/issuer pages; ALT design against ClinicalTrials.gov and issuer statistics.
- Futures limitation: Yahoo's ES daily bar implied +0.65% while Reuters' contemporaneous narrative snapshot reported S&P E-minis −0.22%; contract/session baselines differ. The report therefore supplies the outright Yahoo level and explicitly avoids a synthesized percentage. NQ likewise has no asserted comparable move.
- Source failures: CNBC RSS tunnel failed; the current CNBC article and Reuters were accessible alternatives. WSJ RSS loaded but was stale (Jan. 2025) and was discarded. FDA newsroom extractor rate-limited; official Fed/BLS/BEA calendars and company/registry materials covered today's relevant catalysts, so no unavailable data claim is made.
- No fabricated inputs: no analyst rating, consensus earnings estimate, premarket stock price, FDA outcome, borrow availability/fee or unpublished trial result is asserted. Scores are transparent judgment, not market data.